These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20473949)

  • 1. MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.
    Srivastava MK; Bosch JJ; Wilson AL; Edelman MJ; Ostrand-Rosenberg S
    Int J Cancer; 2010 Dec; 127(11):2612-21. PubMed ID: 20473949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
    Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.
    Srivastava MK; Bosch JJ; Thompson JA; Ksander BR; Edelman MJ; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2008 Oct; 57(10):1493-504. PubMed ID: 18322683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.
    Dissanayake SK; Thompson JA; Bosch JJ; Clements VK; Chen PW; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2004 Mar; 64(5):1867-74. PubMed ID: 14996751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
    Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
    Godet Y; Fabre E; Dosset M; Lamuraglia M; Levionnois E; Ravel P; Benhamouda N; Cazes A; Le Pimpec-Barthes F; Gaugler B; Langlade-Demoyen P; Pivot X; Saas P; Maillère B; Tartour E; Borg C; Adotévi O
    Clin Cancer Res; 2012 May; 18(10):2943-53. PubMed ID: 22407833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The induction of cytotoxic T lymphocytes against HLA-A locus-matched lung adenocarcinoma in patients with non-small cell lung cancer.
    Yoshino I; Takenoyama M; Fujie H; Hanagiri T; Yoshimatsu T; Imabayashi S; Eifuku R; Ogami A; Yano K; Osaki T; Nakanishi R; Ichiyoshi Y; Nomoto K; Yasumoto K
    Jpn J Cancer Res; 1997 Aug; 88(8):743-9. PubMed ID: 9330606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
    Ilkovitch D; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
    Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
    Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
    Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
    Raez LE; Cassileth PA; Schlesselman JJ; Padmanabhan S; Fisher EZ; Baldie PA; Sridhar K; Podack ER
    Cancer Gene Ther; 2003 Nov; 10(11):850-8. PubMed ID: 14605671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.
    Bosch JJ; Iheagwara UK; Reid S; Srivastava MK; Wolf J; Lotem M; Ksander BR; Ostrand-Rosenberg S
    Cancer Immunol Immunother; 2010 Jan; 59(1):103-12. PubMed ID: 19557412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic parameters as significant prognostic factors in lung cancer.
    Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Konaka C; Kato H
    Lung Cancer; 2002 Aug; 37(2):161-9. PubMed ID: 12140139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
    Kobayashi H; Wood M; Song Y; Appella E; Celis E
    Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
    Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
    Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous CD4
    Veatch JR; Jesernig BL; Kargl J; Fitzgibbon M; Lee SM; Baik C; Martins R; Houghton AM; Riddell SR
    Cancer Immunol Res; 2019 Jun; 7(6):910-922. PubMed ID: 31043415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer.
    Bixby DL; Yannelli JR
    Int J Cancer; 1998 Dec; 78(6):685-94. PubMed ID: 9833760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.
    Neumann F; Wagner C; Stevanovic S; Kubuschok B; Schormann C; Mischo A; Ertan K; Schmidt W; Pfreundschuh M
    Int J Cancer; 2004 Nov; 112(4):661-8. PubMed ID: 15382048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.